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Abstract
GNE myopathy is an ultra-rare autosomal recessive disease, which starts as a distal muscle weakness and ultimately leads
to a wheelchair bound state. Molecular research and animal modelling significantly moved forward understanding of
GNE myopathy mechanisms and suggested therapeutic interventions to alleviate the symptoms. Multiple therapeutic
attempts are being made to supplement sialic acid depleted in GNE myopathy muscle cells. Translational research field
provided valuable knowledge through natural history studies, patient registries and clinical trial, which
significantly contributed to bringing forward an era of GNE myopathy treatment. In this review, we are
summarising current GNE myopathy, scientific trends and open questions, which would be of significant
interest for a wide neuromuscular diseases community.
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Background
History of GNE myopathy
GNE (bifunctional UDP-N-acetylglucosamine 2-epimerase/
N-acetylmannosamine kinase) myopathy has been de-
scribed for first time in 1981 by Ikuya Nonaka and col-
leagues as a distal myopathy with rimmed vacuoles and
lamellar (myeloid) body depositions thus receiving the
name of “Nonaka Distal Myopathy” or “Distal Myopathy
with Rimmed Vacuoles” (DMRV) [1]. In 1984, Argov Zohar
described a unique disorder presenting in 4 Iranian-Jewish
families as a “Rimmed Vacuole Myopathy” or “Quadriceps
Sparing Myopathy” (QSM) with characteristic clinical
features [2]. Later, this disorder was also termed as
“Hereditary Inclusion Body Myopathy” (HIBM) or
hIBM, due to the histological similarities to Inclusion
Body Myositis (IBM) [3].
In 1995, Mitrani-Rosenbaum and co-workers linked
the origins of Persian Jewish QSM to chromosome 9 [4].
Approximately two decades after, in 2001, the Mitrani-
Rosenbaum group identified mutations in the causative
gene GNE, which encodes for the N-acetylglucosamine
epimerase/ N-acetylmannosamine kinase (GNE) [5, 6].
The identified gene confirmed that those myopathies
(DMRV, QSM, HIBM and IBM2) in fact represent the
same neuropathological condition [6]. However, since
the identification of GNE as the disease causative gene,
the different historic names for this disorder continue to
be used by research groups worldwide. For that reason,
a consortium of researchers working on various aspects
of this disease has decided in 2014 to unify the name
and call it GNE myopathy [7].
Clinical presentation
Symptoms
GNE myopathy has an estimated worldwide prevalence
of 1/ 1.000.000 [8, 9]. The spectrum of classical clinical
presentations which was initially described in 1981 and
1984 remained unchanged [1, 2] and was complemented
with broader spectrum of rarer and cohort specific
symptoms. The first appearance of symptoms occurs
most frequently in the third decade of life, although, few
early onset cases (at 10 years of age) and late onset in
the 5th decade have been reported [3]. The typical clin-
ical presentation begins with distal weakness in the legs
(foot drop) due to distal leg muscle weakness (Fig. 1),
followed by slowly progressing muscle weakness and
atrophy of lower (more frequent on the tibialis anterior
[10]) and upper extremity muscles with relative sparing
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of the quadriceps [2]. Notably, the presentation of strong
quadriceps in spite of major involvement in other leg
muscles is still the best clinical signpost for the diagnosis
of GNE myopathy as it is rarely found in other neuro-
muscular disorders [3].
The cause of the quadriceps sparing remains one of
the enigmas of this condition [11]. The discovery of
molecular mechanisms explaining the observation of a
prevented muscle group might open new avenues for
the development of further therapeutic intervention
concepts [3]. Slow progression to the proximal muscula-
ture and the upper limbs warrant that patients may
maintain independent walking for long time relying on
the hip constitution [12]. Majority of the GNE patients
retain the quadriceps sparing through several decades,
while a minority (5%) have various degrees of quadriceps
weakness early on [3].
A pattern of muscle weakness in upper limbs is variable
and can mimic scapuloperoneal syndrome or include vari-
ous degrees of hand weakness [8]. It has been described
that patients with onset in proximal leg muscles might
mimic an unusual pattern of limb girdle muscular
dystrophy [13]. Consequently, this unusual clinical presen-
tation may delay diagnosis but in retrospect both clinical
and imaging features show that the posterior thigh mus-
cles become markedly affected while the quadriceps is
spared [8]. A recent study reported that “Beevor sign” is a
common feature in GNE patients of Indian origin. “Beevor
sign” is an upward movement of the umbilicus on neck
flexion, indicating weakness of hip flexors and lower
abdominal muscles compatible with an ascending pattern
of muscle involvement [9]. This sign is characteristic of
T9-T10 spinal cord injury and fascioscapulohumeral
muscular dystrophy (FSHD) and observation of it in GNE
myopathy has so far been cohort specific.
Other than for the muscle weakness and atrophies, the
neurological examination is usually unremarkable with-
out sensory disturbances, normal or low (due to muscle
weakness) tendon reflexes, and normal cranial nerves
examination. GNE myopathy is not associated with
cognitive impairment.
Muscle imaging
Imaging of skeletal muscles, especially MRI, is becom-
ing more available in clinical practice and serves as a
valuable non-invasive tool helping to better diagnose
patients at early stages. Both T1 and T2-weighted
sequences are used to get a comprehensive picture of
the nature of muscle damage. Canonical presentation
of GNE myopathy often reflects clinical presentation,
where distal leg muscles, specifically anterior com-
partment, are severely affected at early stages of the
disease, while quadriceps stays preserved over a long
period of time, especially compared to the posterior
compartment thigh muscles significantly replaced by
fatty tissue. Selective quadriceps sparing, is often sym-
metrical, but noticeable degree of asymmetry has also
been reported [14].
A retrospective systematic review of 13 GNE myop-
athy patients describes detailed assessment of 37 mus-
cles at different stages of the disease [15]. The authors
find that the following muscles were consistently in-
volved at early stages in patients with typical and atyp-
ical clinical presentation: biceps femoris short head,
gluteus minimus, tibialis anterior, extensor hallucis and
digitorum longus, soleus and gastrocnemius medialis.
They also observed a more selective sparing of quadri-
ceps with vastus lateralis been the least affected part,
even at advance stages of the disease, while rectus
femoris, vastus intermedius and vastus medialis showed
variable degree of fatty replacement.
Pelvic muscles and muscles constituting abdominal wall
are not affected at early stages of the disease, but fatty and
fatty-fibrous tissue infiltration of those muscles appear
with the disease progressing further [16]. This may lead to
Fig. 1 Distal muscle weakness in a GNE myopathy patient
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difficulty keeping balance, flabby abdomen and positive
Beevor’s sign, where proximal supra-umbilical part of
rectus abdominis is replaced by fatty tissue, while infra-
umbilical part is preserved [9]. Pelvic muscle MRI also
shows abnormal iliopsoas, pectineus and gluteus minimus
[9], gluteus maximus [17], medius [16].
For differential diagnosis, it is important that simultan-
eous involvement of semimembranosus, semitendinosus
and tibialis anterior point towards GNE myopathy and
helping to distinguish from other myopathies [16].
Muscles in younger patients that appear normal in T1,
occasionally show hyperintensities in T2-weighted se-
quences, which may indicate a degree of inflammation
[16]. This corresponds to biopsy findings, where signs of
inflammation were found in some GNE patients at early
stages of the disease [18].
Neurophysiology
Needle electromyography (EMG) shows myopathic
changes in the examined muscles [16, 17, 19]. Spontan-
eous activity in form of fibrillation potentials and posi-
tive sharp waves might be detected [20]. The EMG
findings usually correlate with the clinical presentation.
Thus, since anterior compartment of the lower limb gets
affected in the first instance, EMG myopathic features
are also more evident when assessed in this compart-
ment [17]. Occasionally, EMG findings in GNE myop-
athy can be difficult to interpret and be reminiscent of
EMG patterns in active myositis. This may have been
the case in a patient, where GNE myopathy (onset at age
42) was preceded by systemic lupus erythematosus
(positive antinuclear antibodies) and arthritis (onset at
age 23) [21], but there are also some cases of GNE
myopathy reported that showed strong inflammatory
infiltrates histologically [18].
Lung function test
It is generally considered that GNE myopathy does not
predispose to respiratory failure. Relatively large cohort
studies in the UK and Iran reported that respiratory
function was not affected and FVC was normal in all
patients [14, 20]. A more systematic prospective study,
followed 24 patients for 1 year in Japan, showed that
respiratory function is preserved in ambulant GNE
patients and there were no changes in FVC over a year.
In non-ambulant subset of the patients (n = 15) mild to
moderate decrease of FVC (mean 74.5% SD ± 19.3%)
was observed and it dropped further over the observa-
tion year (mean 69.8% SD ± 19.2, p = 0.034). A small
number of severely affected patients have been reported
using nocturnal non-invasive positive pressure ventila-
tion (NPPV) [22]. Mild to moderate decrease of FVC
(60-75%) was also observed in another cohort study,
noting that respiratory muscles were only sub-clinically
affected even at advance stages of the disease in bedrid-
den patients [10].
These findings suggest no additional risk of respiratory
failure to ambulant patients; non-ambulant patients
might be at higher risk and therefore annual monitoring
of respiratory function in non-ambulant GNE patients
may be advisable to timely manage the situation in case
of significant decrement of lung function.
Cardiac studies
There is a limited number of studies, which systematic-
ally assessed cardiac function in GNE patients. Based on
the limited number of studies, shared clinical experience
of specialised neuromuscular centres and case reports, it
considered that cardiac impairment is not linked to
GNE myopathy. Here we will refer to two large studies,
which specifically addressed analysis of cardiac function:
The first study assessed cardiac function in 33 Roma
patients, using ECG and EchoCG. Minor to mild
structural and rhythm abnormalities were detected in
nearly half of the evaluated patients, such as impaired
relaxation and repolarization. Three patients had
borderline ejection fraction (EF – 50–55%) values. For
the data interpretation, it is important to note that
some of the above findings are subclinical, and pa-
tients had other co-morbidities and cardiovascular risk
factors e.g. smoking (in all patients), hypertension
and/or diabetes (in 18%).
A prospective natural history study conducted in
Japan, followed 24 patients for 1 year and conducted
ECG, Holter ECG and UCG. Two of these patients pre-
sented with minor to moderate conduction and rhythm
abnormalities i.e. right bundle branch blocks (one
complete and one incomplete), a 1st degree atrioven-
tricular block with sinus bradycardia due to beta-blocker
use, and a non-specific ST-T change (but normal UCG),
sinus tachycardia and non-specific ST-T changes. Ejec-
tion fraction was normal in all patients. Patients with
ST-T changes had diabetes mellitus and/or hypertension.
The study did not show any disease-related abnormal-
ities or any increased risk of cardiomyopathy in ambu-
lant or non-ambulant GNE patients [22].
Presented data did not show any disease specific
abnormalities or a consistent link between the GNE my-
opathy and increase the risk of conduction, arrhythmia,
structural or functional cardiac defects.
Blood tests
Blood tests, routinely available in a clinic, indirectly
reflect muscle damage, i.e. mild to moderate CK eleva-
tion [14], sometimes with a mild ALT elevation (GGT
normal) and low or normal creatinine. In non-ambulant
patients CK could be within normal range or lower, in
accordance with the reduced muscle bulk. A summary
Pogoryelova et al. Orphanet Journal of Rare Diseases  (2018) 13:70 Page 3 of 15
of main information related to GNE myopathy and its
clinical presentation is given in Table 1.
An anecdotal case of mild to moderate thrombocytopenia
have been reported in two siblings with GNE myopathy.
Platelet levels varied between 1.1 × 10^9 /L and 16.2 × 10^9
/L. Thrombocytopenia, was characterized by shortened
platelet lifetime rather than ineffective thrombopoiesis, has
been observed since infancy. Genetic causes of persistent
thrombocytopenia were excluded, and it was suggested that
low platelet count maybe linked to GNE myopathy [23].
Genetics
The GNE gene is located on chromosome 9 and consists
of 13 exons. Each of the individual GNE mRNA splice
variants consist of fewer exons and are two major
isoforms are existing: hGNE1 (GenBank NP_005467) – a
major muscle transcript, and hGNE2 isoform (NP_
001121699) – the longest known sequence to up till
now. hGNE1 was originally described as the GNE pro-
tein which covers 722 amino acids and is, confusingly,
encoded in GenBank by mRNA transcript variant 2
(NM_005476). hGNE2 isoform covers 753 amino acids
and is encoded by the longest GNE mRNA transcript,
variant 1 (NM_001128227) [7]. In the scientific reports,
case reports and cohort studies, mutations are most
commonly reported according to hGNE1 or hGNE2
nomenclature. Notably, hGNE2 differs from hGNE1 by
31 amino acids or 93 base pairs. Thus, a particular mu-
tation nomenclature can easily be converted in accord-
ance to the preferred sequence.
Spectrum of disease causing mutations is wide and con-
stantly growing. Currently, over 150 mutations are known
to be causative for GNE myopathy [24]. Most of these mu-
tations are sporadic or seen in several families or single
cases only. Several mutations have been identified as
founder or recurrent mutations [6, 10, 14, 25, 26]. These
mutations are observed in relatively high frequency in
Japan, Middle East, Roma population in Bulgaria, China
and UK (Table 2.). Most of the currently known patho-
genic variants are missense mutations; other mutations
such as insertions, deletions, large deletions, intronic
mutations [27], and splice site mutations [20, 28] have also
been identified, but are far less common. Rare cases, clin-
ically manifesting as GNE myopathy, but in absence of
two recessive mutations could create a difficulty for
molecular diagnosis. These clinically diagnosed GNE-
cases could be caused by o a more complex molecular
genetic rearrangement, such as copy number variation,
large deletions [29], or deletions leading to Alu-mediated
recombination [30]. Remarkably, so far, no patient has
been identified carrying two nonsense or frameshifting
mutations, suggesting that some basic activity of GNE is re-
quired during early development. Surprisingly, asymptom-
atic cases with confirmed two disease causative mutations
have been described in the literature. This observation
could indicate an incomplete penetrance of the disease, or
even the significance of other (rescue) factors that can miti-
gate the symptoms.
Genotype-phenotype correlation
A potential link between a genotype and a correspond-
ing phenotype has been studied in vitro on cell and
enzyme levels as well as based on patient cohort find-
ings. In the context of in vitro studies, it is important to
note an effect of various GNE mutations on the enzym-
atic activity of the resulting mutant proteins has been
suggested: E. coli and insect cell models showed that
indeed epimerase and kinase enzymatic activity signifi-
cantly varied among selected mutations [31]. Primary
muscle cells with GNE mutations confirmed a significant
reduction in sialic acid levels [32].
Cohort based studies showed marked variability in
severity of the disease [33] suggesting that certain point
mutations are linked to age at onset, presenting symp-
toms, severity and speed of the disease progression [20,
26]. The largest cohort based study suggests that pheno-
typical differences between homozygous and compound
Table 2 List of most commonly identified GNE mutations by
the geographical region
Geographic region or country Founder or high frequency
mutation (hGNE2)
United Kingdom Exon 8 p.Ala662Val
Exon 12p.Asp409Tyr
Bulgaria (Roma population) Exon 11 p.Ile618Thr
Middle East Exon 7 p.Met743Thr
India Exon 12 p.Val727Met
Japan Exon 3 p.Asp207Val
Exon 10 p.Val603Leu
Table 1 GNE myopathy at a glance
GNE myopathy at a glance
Onset 20s
Prevalence 1/ 1.000.000
Genetic Autosomal-recessive
First symptom Foot drop
Additional symptoms Hand weakness
Unusual mimicking of other
myopathic diseases
Scapuloperoneal syndrome, LGMD,
CMT, MTM, LGMD2B
Quadriceps sparing Good strength in 95% of the patients
Progression Slowly from distal to proximal
Beevor’s sign Positive in 90% of an Indian cohort
Cardiac involvement Risk of cardiomyopathy is not
increased
Respiratory involvement Mild to moderate decrease in FVC in
non-ambulatory patients
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heterozygous carriers; in this case one of the most com-
mon mutations in Japan p.Asp207Val seems to predis-
pose to later onset and milder phenotype as opposed to
p.Val603Leu [28]. However, phenotypical studies in pa-
tients homozygous for a single mutation demonstrates
significant inter- and intra- familial variability [10] sug-
gesting that the type of the GNE mutation only partially
contributes to the individual variability and severity of
the disease. Of course, the common problem of ultra-
rare disease studies into consideration, all GNE-popula-
tion based studies were significantly underpowered from
statistical point of view. Hence, a very reliable link be-
tween genotype and phenotype is still lacking and must
be deciphered.
Biopsy findings and pathophysiological studies
on patient-derived muscle
According to the current literature, majority of muscle
biopsies derived from GNE myopathy patients are patho-
logically characterized by the presence of small angular
fibres, formation of rimmed vacuoles and deposition of
various proteins in the muscle fibres [34]. Further patho-
logical hallmarks include the presence of intracellular
Congo red-positive depositions in vacuolated or non-
vacuolated fibres. The rimmed vacuoles can especially be
found in atrophic fibres, which also occasionally contain
the congophilic material immune-reactive to beta-amyloid,
lysosomal proteins, ubiquitin and tau proteins. Inflamma-
tory cell infiltration can also occasionally be found suggest-
ing that muscle inflammation is not sufficient to exclude
the diagnosis of hereditary inclusion body myopathy/ GNE
myopathy [18]. The presence of inflammatory processes
has been observed at early stages of the disease suggesting
that the time point of biopsy procedure has a significant
influence on pathological findings. Of note, based on the
distal nature of this myopathic disease, those neuropatho-
logical findings refer to the distal muscles such as gastro-
cnemius muscle. However, other authors also refer to
affection of proximal muscles such as biceps bracchii and
the quadriceps muscle.
In muscles of GNE myopathy patients, immunohisto-
chemistry allowed the identification of the GNE protein
in sarcoplasm and specifically in myonuclei as well as
within rimmed vacuoles. These vacuoles were also im-
munoreactive for nuclear proteins. In addition, measure-
ments of the size of myonuclei in muscle biopsy
specimen from GNE patients compared to those derived
from ALS patients revealed a significantly larger mean
size in muscle fibres of GNE patients than in ALS
patients. The combined data suggest that myonuclei are
involved in the formation of rimmed vacuoles in GNE
myopathy and that mutant GNE in myonuclei seems to
play some role in this process [35]. In contrast to this
study, results of Krause and co-workers indicate that the
GNE protein is expressed at equal levels in muscle fibres
of patients and normal control subjects and that the
GNE protein did “solely” mislocalization in skeletal
muscle of patients. Therefore, the authors concluded
that impaired GNE function, rather than expression or
mislocalization, may be the key pathogenic factor in the
disease. Moreover, they postulate that for diagnostic pur-
poses, direct GNE gene testing will remain the mainstay
and is not aided by immunohistochemistry or immuno-
blotting using antibodies against the GNE protein [36].
The lack of a GNE-antibody suitable for diagnostic man-
agement of GNE-patients moreover supports this pro-
posed diagnostic procedure.
Already in 2004, biochemical analysis demonstrated
decreased reactivity of skeletal muscle glycoproteins with
the lectins recognizing sialic acid residues, suggesting
that hyposialylation of glycoproteins may be involved in
the etiology of GNE myopathy [37]. In addition, a study
performed by Voermans and colleagues [38] also indi-
cated reduced sialylation of glycoconjugates based on
PNA lectin staining in GNE patient muscle sections
compared to control muscle. Leoyklang and co-workers
analysed the sialylation status of plasma and skeletal
muscle proteins in a biomarker study. Muscle biopsy
specimen derived from GNE patients showed hyposialy-
lation of predominantly O-linked glycans thus suggest-
ing that perturbed protein function based on impaired
post-translational protein-modification is part of the
etiology of GNE myopathy [39]. Huizing and co-workers
studied the glycosylation status of alpha-dystroglycan in
muscle biopsy specimen derived from GNE myopathy
patients of non-Iranian Jewish origin. Remarkably, in all
four muscle biopsies almost absent or markedly reduced
immunolabeling with two different antibodies (VIA4 and
IIH6) to glycosylated epitopes of alpha-dystroglycan
could be observed. In this context, it is important to
note that normal labelling was found using antibodies to
the core alpha-dystroglycan protein, beta-dystroglycan,
and laminin alpha-2. This finding suggested that GNE
myopathy may fall under the category of a so-called
“dystroglycanopathy” [40]. However, in another study,
Broccolini and co-workers [41] also investigated alpha-
dystroglycan (alpha-DG) immunoreactivity in 5 GNE
myopathy patients. Their immunocytochemical and im-
munoblot studies revealed that alpha-DG extracted from
muscle biopsies derived from GNE myopathy patients
was normally expressed and displayed its typical molecu-
lar mass. However, further immunoblot analysis on the
wheat germ lectin-enriched glycoprotein fraction of
muscles and primary myotubes showed a reduced
amount of alpha-DG in 4 out of 5 GNE myopathy pa-
tients (compared to control muscles). As the altered
lectin-binding behavior (reflecting a partial hyposialyla-
tion of alpha-DG) did not affect the laminin binding
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properties of alpha-DG, the authors concluded that sub-
tle changes within the alpha-DG glycosylation pattern
most likely do not play a key pathogenic role in GNE
myopathy [41]. Further studies such as glycoproteomics
may be needed utilizing a higher number of patient and
control samples to draw a final conclusion.
Proteomic profiling (two-dimensional gel electrophor-
esis (2-DE) and iTRAQ) has been performed on muscle
cultures and biopsies of GNE myopathy patients. Out of
the 400 proteins identified in biopsies by iTRAQ, 41
showed altered expression while the 2-DE analysis on
biopsies revealed 26 differentially expressed proteins.
Notwithstanding the fact that two different sources for
protein extraction (muscle primary cultures versus
muscle biopsies) have been utilised and that two differ-
ent methods have been applied, the proteins identified
with altered abundances in each of the analyses were
mainly involved in the same pathways, ubiquitination,
stress response and mitochondrial processes. Interest-
ingly, the most robust cluster was assigned to cytoskel-
eton and sarcomere organisation. Thus, these findings
indicate a possible function of GNE in the muscle fila-
mentous apparatus that could be involved in the patho-
genesis of the myopathy [42]. In another study to
elucidate the pathological mechanisms leading from the
mutated GNE to the myopathic phenotype, Eisenberg
and colleagues [43] attempted to identify early manifest-
ing downstream events. For that purpose, the genomic
expression patterns of muscle specimens from 10 GNE
myopathy patients carrying the p.M712 T mutation and
presenting mild histological changes were compared
with 10 healthy matched control muscles using Gene-
Chip expression microarrays. Three hundred seventy
four differentially expressed genes were identified.
Approximately 20% of the overall differentially expressed
mRNAs of known function were found to encode for
proteins implicated in various mitochondrial processes,
revealing mitochondrial pathway dysregulation. This
finding is in agreement with the results of the proteomic
studies. Further morphological analysis by confocal
microscopy showed a high degree of mitochondrial
branching in cells of GNE myopathy patients. The in-
volvement of mitochondrial processes in the patho-
physiology of GNE myopathy reveals an unexpected
facet, which could at least partially explain the slow
evolution of this disorder [43].
ER-stress and the activation of the unfolded proteins
response (UPR), as the respective cellular defence mech-
anism, have been described in sporadic inclusion-body
myositis (sIBM), In contrast, UPR key players (ATF4,
ATF6, BiP and XBP1) in muscle of GNE patients lacked
any evidence of UPR induction. However, cultured
GNE-h-IBM muscle fibers had a robust UPR response to
experimental ER stress stimuli, suggesting that the GNE
mutation per se is not responsible for the lack of UPR in
GNE-h-IBM biopsied muscle [44]. In contrast, activation
of the unfolded protein response as well as the ubiquitin
proteasome system along with autophagy have been
described in muscle biopsy specimen of eight patients
with GNE myopathy by another group [45] using
immunofluorescence and immunoblotting. Elevated pro-
tein abundance of BiP/GRP78, GRP94, calreticulin and
calnexin (all are major chaperones controlled be the
unfolded protein response) was demonstrated. Moreover,
VCP (important for the ER-associated degradation path-
way) was increased. Increased proteasome activities were
shown by forced cleavage of fluorogenic substrates. 20S
proteasome subunits, three main proteasome proteolytic
activities, and the factors linking UPS and autophagy
system were also increased. The authors concluded that
activation of these cellular defence mechanisms resulted
from intracellular beta amyloid (Aβ) accumulation. Of
note, Fischer and colleagues [46] revealed that the
mRNA-expression of APP significantly correlated with
the expression of αB-crystallin (a molecular chaperone)
and several pro-inflammatory and cell-stress-associated
markers as NCAM, IL-1β, TGF-β, CCL-3, and CCL-4.
Normal appearing fibres displayed an overexpression of
these molecules, and their elevated expression is compat-
ible with an activation of cellular defence mechanisms.
Disease models and pathomechanisms
Sialic acid is an acidic monosaccharide that modifies
non-reducing terminal carbohydrate chains on glycopro-
teins and glycolipids and plays an important role in
different processes such as cell-adhesion and cellular
interactions. Sialic acid has been implicated in health
and disease and is found in terminal sugar chains of
proteins modulating their cellular functions. As UDP-N-
acetylglucosamine 2-epimerase/N-acetylmannosamine
kinase (GNE) is the key enzyme for the biosynthesis of
sialic acid (Fig. 2) it is without any doubt that perturbed
function of the protein results in biochemical conse-
quences. Indeed, GNE mutations can result in two
human disorders, GNE myopathy or sialuria. Moreover,
it has been demonstrated that GNE expression is
induced when myofibers are damaged or regenerating,
and that GNE plays a role in muscle regeneration [47].
However, correlation between mutation-associated re-
ductions in sialic acid production and disease severity is
imperfect and although the underlying pathophysiology
is, at least partially, likely to result from perturbed post-
translational protein modification (hyposialylation of
glycoconjugates; Fig. 2), many mechanisms have been
suggested as possible (downstream) cause of muscle
degeneration such as defects in cytoskeletal network,
sarcomere organization and initiation of apoptosis. Sup-
port for this hypothesis was presented by Salama and
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colleagues [48]. Myoblasts carrying a mutated GNE gene
show a reduction in their epimerase activity, whereby only
the cells carrying a homozygous epimerase mutation also
present with a significant reduction in the overall mem-
brane bound sialic acid. This finding indicates that
although mutations in each of the two GNE domains
result in an impaired enzymatic activity and the same
myopathic phenotype, they do not equally affect the over-
all sialylation of muscle cells. Thus, the pathological
mechanism of the disease may not exclusively be linked to
the impaired sialic acid pathway [48].
In vitro models
As it is known that the mutated hypofunctional GNE is
associated with intracellular accumulation of amyloid
β-peptide (Aβ) in patient muscles (see “biopsy findings
and pathophysiological studies on patient-derived muscle”
section) Bosch-Morató and colleagues [49] addressed the
underlying mechanism by using C2C12 cells and demon-
strated that systematic reduction of sialic acid favors
Aβ1-42 endocytosis in a clathrin and heparan sulfate
proteoglycan-dependent manner explaining the enhanced
Aβ1-42 internalization in myoblasts from a GNE myop-
athy patient. As a consequence, reduced phosphor-AKT
level accompanied by an increase of apoptosis marker pro-
teins could be observed in the patient-derived cells.
To elucidate the role of GNE in cell apoptosis, Singh
and Arya [50] used HEK293 cells overexpressing patho-
logically relevant GNE mutations. These disease-model
cells display defective proliferation, reduced sialic acid-
bound glycoconjugates level and increased apoptosis.
Transmission electron microscopic studies revealed
mitochondrial perturbations which is in line with
altered mitochondrial transmembrane potential in cells
lacking functional GNE. HEK293 cells in which GNE
has either been knocked down or over-expressed with
pathologically relevant GNE mutants (p.D207V and p.
V603 L)show that mutant forms of GNE differ in their
subcellular localizations from the wildtype protein and
sialylation-studies of β1-integrin revealed hyposialyla-
tion along with mislocalisation to internal vesicles. This
mislocalization could be restored upon supplementa-
tion with sialic acid. Fibronectin stimulation caused
migration of hyposialylated β1-integrin to the cell
membrane and co-localization with focal adhesion
kinase (FAK) leading to increased focal adhesion for-
mation. Hence, results of this study demonstrate that
GNE mutations affect β1-integrin-mediated cell adhe-
sion processes [51].
Patzel and co-workers [52] investigated the accumula-
tion of glycosphingolipids by HPLC in patients’ and
control fibroblasts and plasma. The mutant cells exhibited
impaired GNE epimerase activity through a novel imino
sugar resulting in an increase of both, neutral and sialy-
lated glycosphingolipids. Interestingly, treatment of
patient-derived fibroblasts with N-acetylmannosamine (si-
alic acid precursor downstream of GNE epimerase
activity) ameliorated the increased glycosphingolipids con-
centrations. These data may lead to further studies of gly-
cosphingolipids concentrations as a potential biomarker,
not only for GNE myopathy, but also for other disorders
of sialic acid metabolism. Indeed, when studying the tissue
of Gne (p.M712 T/p.M712 T; according to the new no-
menclature p.M743 T/p.M743 T) knock-in mice (de-
scribed below in more detail) elevated glycosphingolipids
concentrations could also be observed supporting the
concept of glycosphingolipids concentrations as a bio-
marker [52]. By focusing on the same mutation in primary
patient –derived myoblasts cultures, Amsili and colleagues
[53] identified that although p.M712 T-mutant GNE and
control myoblasts showed similar patterns of proliferation
and differentiation, upon apoptosis induction, active forms
of caspase-3 and -9 were strongly increased in p.M712 T-
GNE cultures compared to controls, while pAKT, down-
regulated in controls, remained high in patient-derived
cells. These results suggest impaired apoptotic signalling
in GNE-mutant muscle cells. This observation accords
with the findings of different scientific reports [49, 50]. As
satellite cells enable muscle regeneration, these altered
cellular processes most likely contribute to the muscle
mass loss observed in patients [53].
Bennmann and co-workers [54] studied the molecular
effect of a particular amino acid exchange (p.M743 T)
Fig. 2 The bifunctional enzyme UDP-GlcNAc 2-epimerase/ ManNAc
kinase (GNE/MNK), encoded by the GNE gene, catalyzes the first two
committed, rate-limiting steps in the biosynthesis of N-acetylneuraminic
acid (sialic acid)
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found in severe cases of GNE myopathy and demon-
strated that amino acid exchanges introducing potential
phosphorylation/O-GlcNAcylation sites result in in-
creased O-GlcNAcylation and increased stability of the
mutant protein suggesting that the balance of phosphor-
ylation and O-GlcNAcylation is involved in the modula-
tion of efficiency GNE. In vitro investigation of the same
mutation by surface plasmon resonance and microscale
thermophoresis analysis revealed that wildtype GNE
interacts with α-actinin 2 with a 10-fold higher affinity
compared to the GNE-α-actinin 1 interaction (which has
been described before; [55]). In contrast, p.M743 T GNE
displays a 10-fold lower binding affinity to α-actinin 2.
This pathophysiological finding is most likely based on
perturbed protein-protein binding and leads to func-
tional imbalance in skeletal muscle [56]. Further studies
utilizing GNE p.M743 T-mutant myoblasts revealed in-
creased level of activated PTEN and PDK1 [57].
In another study [58], BJAB K20 cells, as an in vitro
system lacking endogenous GNE activity based on
epigenetically-based silencing have been used to introduce
expression of wild-type GNE or mutant forms. Latter ones
either affected the kinase (p.M712 T) or the epimerase (p.
D176V) domain. Moreover, an artificial open reading frame
encoding a GNE protein lacking the epimerase domain has
been introduced into BJAB K20 cells and subsequent.
Lectin binding and mass spectrometry analysis revealed
that GNE deficiency affects the structure of cell-surface gly-
cans. Apart from low levels of sialylation, GNE-deficient
cells produced distinct N-linked glycan structures with in-
creased branching and extended poly-N-acetyllactosamine.
Interestingly, N-linked glycans produced by GNE-deficient
cells displayed enhanced binding to galectin-1, indicating
that changes in GNE activity can alter affinity of cell-
surface glycoproteins for the galectin lattice. This in turn
indicates a pathomechanism by which GNE activity might
affect signaling through cell-surface receptors [58].
Grover and co-workers used Dictyostelium discoideum
(species of soil-living amoeba) to study expression and
secretion of wildtype and mutant forms of GNE.
Whereas upon starvation, wildtype GNE (as a function-
ally fully active enzyme) was secreted into the medium
from secretory vesicles, secretion of both epimerase and
kinase mutant forms of GNE was found to be drastically
reduced. This alternative in vitro system can be used for
biophysical characterization of GNE and may give an in-
dication of the pathogenicity of mutant variants of the
protein to evaluate the potential pathogenicity of newly
identified GNE mutations [59].
Mouse models
Malicdan and colleagues generated the Gne−/−GNED176V-
Tg mouse model which exhibits late onset progressive
muscle weakness and atrophy and pathological changes like
those observed in patients. Those changes included
presence of rimmed vacuoles, especially in atrophic fibers,
which also occasionally contain congophilic material. In
addition to these myopathic findings, the mouse model also
showed hyposialylation of serum and other tissues from
birth and exhibited late onset myopathy accompanied by
mild serum creatine kinase elevation from 21 weeks of
age [60]. Moreover, it has been demonstrated that the
myopathic phenotype was prevented by oral administration
of N-acetylneuraminic acid, N-acetylmannosamine, and sia-
lyllactose (favorable improvement in survival rate, motor
performance, muscle force, muscle atrophy, and muscle de-
generation), suggesting that hyposialylation is an important
factor in the pathogenesis of GNE myopathy [61]. Several
synthetic sugar compounds that may significantly increase
sialylation and show measurable effects were screened with
the result that tetra-O-acetylated N-acetylmannosamine in-
creased cell sialylation most efficiently, leading to a more
dramatic, measurable effect and improvement in muscle
phenotype [62]. These findings provided a proof of concept
in sialic acid-related molecular therapy with synthetic
monosaccharides. In another follow-up study, temporal
changes in the overall motor performance of this model
were addressed: studies revealed muscle weakness, de-
creased whole muscle mass and cross-sectional area (CSA),
and reduced contractile power in an age-related manner.
Investigation of single-fiber CSA supported the finding of
muscle atrophy and displayed affection of both, type I and
type II fibers. In older animals, RVs and intracellular inclu-
sions were seen in type IIA fibers, further aggravating
reduction of force and specific increase in twitch-tetanus
ratio. This effect was – in accordance with the nature of a
distal myopathy in patients – very pronounced in gastro-
cnemius muscles. These results implicate the important
role of atrophy in the pathophysiology of GNE myopathy
[63]. Yonekawa and co-workers [64] examined the efficacy
of sialic acid supplementation on symptomatic Gne−/
−GNED176V-Tg mice presenting with active progressive
muscle degeneration. Hereby, the therapeutic effect of a
less metabolized sialic acid compound (6′-sialyllactose) or
free sialic acid (N-acetylneuraminic acid) was studied by
oral, continuous administration to 50-week-old mice for
30 weeks. As readout-measures, motor performance in liv-
ing mice and spontaneous locomotion activity on a running
wheel have been investigated at 50, 65, 72 and 80 weeks of
age. In addition, fibre size, force production and general
pathology were studied in gastrocnemius muscle along with
level of sialic acid. Notably, spontaneous locomotion activ-
ity was recovered in 6′-sialyllactose-treated mice, while
NeuAc-treated mice slowed the disease progression and 6′-
sialyllactose-treatment showed a positive effect towards
restoration of hyposialylation in muscle and consequently
to robust improvement in the muscle size, contractile pa-
rameters, and pathology. This beneficial effect could not be
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observed for NeuAc. Hence, the results indicate that GNE
myopathy can be treated even at a progressive stage and
6′-sialyllactose has more remarkable advantage than
free sialic acid, providing a conceptual proof for clin-
ical use in patients.
A transgenic mouse that expressed the human GNE p.
V572 L mutation (the most prevalent among Japanese GNE
patients) has been generated, and crossed this with Gne(+/
−) mouse to obtain Gne−/−hGNEV572L-Tg animals. Mutant
mice exhibit marked hyposialylation in serum, muscle and
other organs such as kidney. Notably, reduction in motor
performance can only be seen from 30 weeks of age and a
compelling finding is the development of beta-amyloid
deposition in myofibers by 32 weeks. Latter one clearly pre-
cedes rimmed vacuole formation at 42 weeks [65]. Interest-
ingly, the Gne−/−hGNEV572L-Tg animals moreover exhibit
hyposialylation and intracellular amyloid deposition
before the characteristic rimmed vacuoles can be
detected, suggesting that autophagy might be a downstream
effect to hyposialylation and amyloid deposition in GNE
myopathy [66]. In 2012, Ito and colleagues [67] further
reported that renal pathology was based on hyposialylation
of podocalyxin. Administering Neu5Ac to the mutant mice
from embryonic stages significantly suppressed the
renal pathology and partially recovered the glomerular
glycoprotein sialylation. However, activation of the
unfolded protein response in kidney and skeletal
muscle has not been studied in this mouse model.
Cho and co-workers [68] performed a study utilizing an-
other in vivo model of GNE myopathy, the Gne−/
−hGNEV207L-Tg mice [60]. Results of their studies
provided evidence for function of sialic acids as a ROS
scavenger and thus improved the current understanding
on how sialic acid deficiency contributes to disease
pathology: their studies revealed that proteins decisive for
proper muscle function and maintenance were highly
modified by S-nitrosylation. Additionally, oxidative stress-
responsive genes were significantly upregulated in hypo-
sialylated murine muscles (same could be confirmed in
patient derived muscle biopsies in turn highlighting the
suitability of the mouse model) as a reaction to elevated
production of reactive oxygen species (ROS). Notably, in-
creasing overall sialylation by extrinsic sialic acid intake
reduced ROS and protein S-nitrosylation. Notably,
N-acetylcysteine (an antioxidant) intake ameliorated
muscle weakness and atrophy in the mouse model [68].
Moreover, the authors provided molecular insights into
the associated muscle fibre degeneration by demonstrating
that two well-known muscle atrophy markers (atrogin-1/
Fbxo32 and MuRF1/Trim63) present with elevated
transcript level in the diseased murine muscle fibres,
suggesting that common proteolytic systems of muscle
atrophy are involved in the pathophysiology of GNE
myopathy [68].
As the most frequent mutation in GNE myopathy pa-
tients is the Middle Eastern (Persian-Jewish) founder
mutation p.M712 T, Sela and co-workers [69] generated
Gne(p.M712T/p.M712T) knock-in mice. Notably, a high mor-
tality rate has been observed in the first generation
based on renal failure. However, the following genera-
tions were classified into 3 phenotypic categories: severe,
mild and without apparent phenotype. Further crossing
of mice lacking an apparent phenotype allowed the es-
tablishment of a colony with long-term survival. These
animals did not show any signs of a kidney phenotype
but also no apparent muscle phenotype for up to
18 months of age. And although no clear correlation
was found between the expression of the two Gne
mRNA isoforms in skeletal muscle and genotype or
phenotype, expression of isoform 2 mRNA was signifi-
cantly higher in the kidney of Gne(p.M712T/p.M712T)
animals. Notably, expression of proteins involved in the
modulation of the unfolded protein response such as
BiP and CHOP as well as enhanced splicing of Xbp1 has
been found in the skeletal muscle but not in the kidney
of the homozygous mutant animals. This observation
supports the results of Li and co-workers [45] suggesting
that activation of the unfolded protein response might
prevent GNE-diseased muscle fibres from death (see
below). Quantitative RT-PCR analysis of St 3 gal5 (GM3
synthase) gene expression and HPLC-based quantifica-
tion of GM3 ganglioside were conducted on Gne(p.
M712T/p.M712T) and control mice. Results showed that
St 3 gal5 mRNA levels were significantly decreased in
skeletal muscle derived from the mutant animals. In
accordance with this finding, GM3 ganglioside levels
also showed a significant decrease in skeletal muscle
derived from the mutant animals. Although Gne(p.M712T/
p.M712T) mice were described to suffer from severe
glomerular proteinuria (see above), no GM3 alterations
were noted in kidneys, suggesting a tissue specific
alteration of gangliosides. Hence, the homozygous p.
M712 T mutation in GNE hampers the muscle ability to
synthesize normal levels of GM3 [70]. Another study
focused on the beneficial effect of oral monosaccharide
supplementation as a therapy to reverse renal and muscle
hyposialylation. Both, effectiveness for prophylaxis (at the
embryonic and neonatal stages) and therapy (after the
onset of symptoms) were studied by evaluating renal and
muscle hyposialylation: oral mannosamine (ManN), (but
not sialic acid (Neu5Ac), mannose (Man), galactose (Gal),
or glucosamine (GlcN)) administered to pregnant female
mice has a prophylactic effect on renal hyposialylation,
pathology and neonatal survival of mutant offspring, as
already shown for N-acetylmannosamine (ManNAc) ther-
apy [71]. As GNE myopathy patients require treatment in
adulthood (after onset of symptoms), Niethamer and col-
leagues [71] additionally administered ManNAc (1 or 2 g/
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kg/day for 12 weeks), Neu5Ac (2 g/kg/day for 12 weeks),
or ManN (2 g/kg/day for 6 weeks) in drinking water to
6 months old animals. Notably, all three therapies mark-
edly improved the muscle and renal hyposialylation. This
was clearly evidenced by lectin histochemistry for overall
sialylation status and immunoblotting of specific sialopro-
teins. These combined findings clearly support further
evaluation of oral ManNAc, Neu5Ac and ManN as a po-
tential therapy for GNE myopathy.
In 2012, Mitrani-Rosenbaum and co-workers applied a
gene therapeutic approach as an interventional concept
to treat GNE myopathy: AAV8 viral vectors carrying
wild type human GNE cDNA were able to transduce
murine and human muscle cells carrying GNE muta-
tions. Based on this promising finding, in the next step,
the authors intravenously administered this viral vector
to healthy mice allowing expression of the GNE mRNA
(and of the co-expressed luciferase protein) for 6 months
in skeletal muscles. Hereby, no pathological signs of
focal or general toxicity, neither from the virus particles
nor from the wild type human GNE overexpression
could be observed. This sustained and safety expression
of human GNE in normal mice after gene transfer based
on AAV8 systemic delivery suggests that GNE-based
gene therapy might represent a promising concept to
treat the disease [72].
Zebrafish model
By in situ hybridization and Gne promoter-driven fluor-
escent transgenic fish generation, Daya and colleagues
[73] investigated the spatiotemporal expression pattern
of the zebrafish gne gene and have shown that it is
highly conserved compared with the human ortholog.
Morpholino (MO)-modified antisense oligonucleotides-
based gene depletion resulted in a significantly reduced
locomotor activity accompanied by distorted muscle
integrity, including a reduction in the number of muscle
myofibres. Muscle fibre pathology was moreover con-
firmed by electron microscopy studies, where large gaps
between sarcolemma could be detected. However, sarco-
meric structures were maintained. The combined data
highlight a prominent role of GNE also in zebrafish and
suggest that the zebrafish model is a suitable animal
model for further pathophysiological studies and/ or
testing of therapeutic intervention concepts.
Biomarkers
Valles-Ayoub and colleagues developed a method to allow
detection of serum NCAM sialylation using Western blot,
and tested serum samples from several GNE-patients.
Their results showed a clear difference in polysialylated
and hyposialylated forms of serum NCAM and revealed
that NCAM is hyposialylated in patient serum samples,
suggesting changes of NCAM-sialysation to a potential
serum biomarker for GNE myopathy [74]. In this context,
it is important to note that NCAM plays a crucial role for
stability of (re)-innervated neuromuscular junctions [75]
and that altered NCAM secretion might influence this
event. However, systematic studies on neuromuscular
junctions in GNE myopathy are still lacking. In addition, a
systematic study of a large patient cohort (ideally with a
diversity of GNE mutations) would be needed to define
changes of NCAM-sialysation as a reliable serum bio-
marker for this disease.
Extent of pre-existing serum antibodies to rAAVrh74,
rAAV1, rAAV2, rAAV6, rAAV8, and rAAV9 has been
examined in patients suffering from Duchenne muscular
dystrophy (DMD), Becker muscular dystrophy (BMD),
inclusion body myositis (IBM), and GNE myopathy. The
rationale behind this study was that recombinant adeno-
associated virus (rAAV) is a commonly used gene ther-
apy vector for the delivery of therapeutic transgenes in a
variety of human diseases, but pre-existing serum anti-
bodies to viral capsid proteins can greatly inhibit rAAV
transduction of tissues [76]. Compared to serum samples
derived from control individuals, patients with measur-
able titers to one rAAV serotype showed titers to all
other serotypes analyzed. Hereby, average titers to
rAAV2 showed to be highest in all patients. Of note,
50% of all IBM and GNE patients also had antibody
titers to all rAAV serotypes, while only 18% of DMD and
0% of BMD patients did. These data indicate a concern
of treatment blockage by pre-existing serum rAAV anti-
bodies in GNE myopathy [76]. However, a systematic
study of pre-existing serum rAAV antibodies in serum
samples derived from animal models are still lacking and
a potential positive result would not only further dem-
onstrate their suitability as a good phenocopy of the
human disease but also allow to systematically address
the hypothesis that these pre-existing antibodies might
negatively influence gene therapeutic concepts utilizing
a viral approach.
As the pathophysiology of GNE myopathy presumably
involves aberrant sialylation, sialylation status of blood-
based glycans was studied as potential disease marker by
Leoyklang and co-workers [39]. Compared to control
samples, O-linked glycome of patients’ plasma showed
increased amounts of de-sialylated Thomsen-Friedenreich
(T)-antigen, and/or decreased amounts of its sialylated
form (ST-antigen). Interestingly, hereby all GNE patients
presented with increased T/ST ratios compared with con-
trols. Further studies of muscle biopsy specimen derived
from GNE patients showed hyposialylation of predomin-
antly O-linked glycans. Based on their findings, the
authors postulated that plasma T/ST ratios are a robust
blood-based biomarker for GNE myopathy [39].
Myostatin is secreted primarily from skeletal muscle
and can potently suppress muscle fiber growth and has
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hence the ability to regulate skeletal muscle mass. This
in turn has sparked interest in the development of anti-
myostatin therapies for a variety of muscular disorders.
Burch and colleagues have measured the serum myosta-
tin concentration in seven genetic neuromuscular dis-
order patient populations including GNE myopathy. For
that purpose, immunoaffinity LC-MS/MS has been
applied and average serum concentrations of myostatin
in seven muscle disease patient groups, including GNE
patients, were significantly less than in controls. Hereby,
myostatin level correlated with clinical measures of
disease progression in GNE myopathy. These findings
suggest the potential of myostatin as a biomarker of
disease progression in GNE myopathy [77]. However,
further studies investigating larger patient cohorts would
be helpful to determine the utility of myostatin as a reli-
able blood biomarker for GNE myopathy. In the same
context, it would be very interesting to study the level of
follistatin and correlate the myostatin/ follistatin ratios
with the genotype as well as the severity of the disease.
In addition, study of myostatin/ follistatin level in the
above-mentioned mouse models would give further
insights into their suitability as appropriate animals
models for GNE-myopathy.
Interventional strategies
Therapy development
There is no approved treatment for GNE myopathy to
date. Current patient management is focused on improv-
ing quality of life by addressing major symptoms. This
includes physiotherapy, selection of walking assistive
devices and orthoses, psychological support, pain man-
agement and nocturnal ventilation where relevant, mo-
bility devices (e.g. wheelchair or scooter), carer help and
alternative professional development.
Significant effort is currently being put in translational
research to find a treatment for GNE myopathy. This in-
cludes clinical trial readiness and baseline data collection
via national and international patient registries (Remudy
“www.remudy.jp” and International GNE registry “www.
gnem-dmp.com”). Multicentre Natural history studies
conducted by NIH (USA) and Ultragenyx Pharmaceutical
(USA) contribute to a systematic approach of studying
versatile presentation of GNE myopathy and assessment
of muscle decline in a given period of time.
Current statistics shows that Remudy registry has
over 200 registered patients in Japan, GNEM-DMP has
over 300 patients registered worldwide. Both registries
are recruiting patients and collecting mandatory data
items. In addition, International GNE registry collects
medical history, longitudinal progression, and quality of
life; Remudy collects clinical data on lung function,
ambulation and CK level. Both registries communicate
to registry participants to inform them about relevant
scientific studies, advances in the research and patient
advocacy meetings.
Two natural history studies of GNE myopathy are
currently in progress. One is conducted by Ultragenyx
Pharmaceutical (USA), this is multicentre, inter-
national study, with > 100 patients recruited and
followed up between 1 and 4 years (www.clinicaltrials.
gov ID NCT01784679). The study collects longitudinal
data including medical history, serum biomarkers,
physiotherapy and patient-self reported outcomes.
Another study is a single-centre, prospective Natural
History study conducted at the NIH (USA) that has
recruited > 50 patients, with a plan to follow them up
for up to 6 years (NCT01417533). The study evaluates
muscle strength, function and subjective patient-
reported outcomes, along with serum and urine bio-
markers and muscle imaging. Preliminary results of
the natural history studies, demonstrated in the
neuromuscular meetings and conferences, show slow
but measurable decline of muscle strength in upper
and lower extremities and decline in general physical
activity and ability to perform daily living activities
over the time.
Disease pathomechanism and animal model studies
suggested that supplementation of ManNAc or sialic
acid is beneficial in GNE myopathy [61, 64]. Therefore,
the idea of exogenous replenishment of Sialic acid was
taken forward into clinical investigations. Several thera-
peutic approaches have been suggested as a potential
treatment for GNE myopathy. Therapeutic approaches
were based on the pathway of the disease, which affect
Sialic acid synthesis, and effectively results in a sialic
acid deficiency. The following compounds have been
studied as a source of sialic acid supplementation: Ace-
neuraminic acid, ManNAc, and immunoglobulin (IVIG).
IVIG therapy was administered to 4 patients at a loading
dose of 1 g/kg on two consecutive days followed by 3
doses of 400 mg/kg at weekly intervals. The study showed
mild improvement in quadriceps, shoulder muscle
strength and in 8 other muscle groups by the end of the
study. Patients self-reported and objective measures were
variable and not presented in detail. Immunohistochemi-
cal staining and immunoblotting of muscle biopsies for
alpha-dystroglycan and NCAM did not show that IVIG
treatment improves muscle syalilation. Although study
showed some mildly positive signs and was tolerated with-
out significant adverse events it was considered not to
pursue IVIG therapy any further [78].
Aceneuraminic acid (Ace-ER) and ManNAc were studied
to a much greater extent. Ace-ER went all the way from
preclinical studies to the completing Phase 3 double blind
placebo-controlled study in 2017. Preclinical studies and
early clinical studies showed stabilisation and slower decline
of muscle function [33, 79], (NCT02731690, NCT02
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736188, NCT01517880, NCT01830972, NCT01236898).
Phase 2 clinical trial showed dose-dependent improvement
in muscle strength relative to placebo in some muscle
groups. Unfortunately, the Phase 3 study did not meet any
primary or secondary end points and, therefore it was con-
cluded that Ace-ER was safe and had no or very little effect
on GNE myopathy progression (NCT02377921).
The intermediate of the sialic acid biosynthesis pathway
- N-acetyl-D-mannosamine (ManNAc) is another poten-
tial therapeutic option. A Phase 1 trial (NCT01634750) of
ManNAC is complete and a Phase 2 trial (NCT02346461)
is currently ongoing. ManNAc is reported to be safe with
recent publications suggesting that ManNAc restores the
intracellular biosynthesis of sialic acid, including in pa-
tients homozygous for kinase domain mutations.
A single attempt of gene therapy in a GNE patient was
documented in 2011 [78], the results showed modest im-
provement, but this therapy has never been followed up
or tested in a well-designed and approved clinical trial.
Translational research projects, including clinical
trial attempts presented here are in development and
new results might appear soon. However, it is clear
that any successful therapy development in this ultra-
rare disease requires a substantial multicentre, inter-
national collaboration.
Diet/ nutrition
Although patients suffering from GNE myopathy do not
require any special diet, a benefit of consumption of
food rich in sialic acid is very likely. Sialic Acid can be
found in milk and dairy products (e.g. whey) as well as
in some exotic meals like Chinese delicacy Yanwo. To
date no research has been conducted to test the hypoth-
esis that food supplementation of sialic acid has any
benefit for the muscle strength in GNE myopathy. One
observational study however suggests that consumption
of traditional whey-based drink in Iran (called “Arshe”
or “Lour”), rich in sialic acid may lead to a slight palli-
ation of symptoms and perhaps to a delay in the age of
onset. Although whey contains a high concentration of
sialic acid, neither of these dietary substances has been
scientifically evaluated for their specific components and
their correlation with muscle strength or other objective
measure. The authors of the paper discuss that in their
opinion further analysis is required to systematically
assess hypothesised effect of dietary supplementation of
sialic acid.
Physiotherapy
GNE myopathy is a slow progressing disorder which
does not have a tendency to contractures. Physiotherapy
and hydrotherapy are recommended under supervision
of experienced physiotherapist. Unsupervised sessions
can also be advised and planned by a specialist to be
conducted at home by patient and their caregiver it has
recently been shown that GNE myopathy patients may
benefit from attending physical therapy or occupational
therapy services to help maintain their functional cap-
acity [12]. Taking the degree of disease progression in
GNE myopathy into consideration, more research is
required to define and improve training protocols and
optimize exercise strategies and routine protocols for
this condition. However, there is valid evidence support-
ing the safety of low to moderate intensity loading exer-
cises [Error! Bookmark not defined.]. Additionally,
exercise may enhance cardiovascular activity and may
help to reduce experienced fatigue [80]. Inclusion of
patients in decision making and planning of the exercise
schedule and intensity will help to maximise outcomes
and self-efficacy in people with this long-term condition
[Error! Bookmark not defined.].
Conclusions
GNE myopathy, discovered over 30 years ago, has now
been studied on many levels ranging from cell and animal
models, to systematic natural history and epidemiology
studies in patients leading to the development of thera-
peutic strategies based on the substitution of sialic acid,
which were tested in clinical trials. Classical presentation
with juvenile or young-adult foot drop in the absence of
sensory deficits, spared quadriceps and rimmed vacuoles
in muscle biopsy specimens should lead to inclusion of
GNE myopathy in differential diagnosis, followed by gen-
etic testing. The disease management currently includes
mobility assistance and support, physiotherapy and man-
agement of other associated symptoms (e.g. musculoskel-
etal pain, pressure sores), however no disease specific
treatment is currently available. Ace-ER (sialic acid) was
envisaged to be a first potential therapy for GNE myop-
athy and showed stabilisation of muscle function in phase
2 clinical trial, however a large and well-conducted
double-blind, placebo-controlled phase 3 study did not
support efficacy of this treatment regimen. Further re-
search into the mechanisms underlying the disease, and
into GNE enzyme function, maybe required to identify al-
ternative treatment options. The GNE enzyme is involved
in sialic acid production and forms a complex with α-acti-
nin 2 which is important for the cell stability and contrac-
tion (https://www.ncbi.nlm.nih.gov/pubmed/27023225).
In the same context, different potential biomarkers have
been identified which might serve as potential readouts
for future therapeutic interventions. Comprehensive stud-
ies using in vitro and in vivo models indicate activation of
the unfolded protein response as an efficient protective
mechanism in this disease. This may have therapeutic sig-
nificance if the protective cascade could be activated by
drug therapy.
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